Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy

BACKGROUND. Reversing immune exhaustion with an anti-PD-L1 antibody may improve human immunodeficiency virus type 1 (HIV-1)–specific immunity and increase clearance of HIV-1–expressing cells. METHODS. We conducted a phase I, randomized, double-blind, placebo-controlled, dose-escalating study of BMS-...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Infect Dis
Autors principals: Gay, Cynthia L., Bosch, Ronald J, Ritz, Justin, Hataye, Jason M., Aga, Evgenia, Tressler, Randall L., Mason, Stephen W., Hwang, Carey K., Grasela, Dennis M., Ray, Neelanjana, Cyktor, Josh C., Coffin, John M., Acosta, Edward P., Koup, Richard A., Mellors, John W., Eron, Joseph J.
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2017
Matèries:
Major Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5790148/
https://ncbi.nlm.nih.gov/pubmed/28431010
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/infdis/jix191
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars